Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Kyndryl Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Kyndryl Holdings Inc trades at $13.26 (market cap $2.97B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | KD | |
|---|---|---|
Market Cap | $5.06B | $2.97B |
Sector | Health | Technology |
52-Week High | $29.41 | $33.14 |
52-Week Low | $20.06 | $10.59 |
Enterprise Value | $4.18B | $5.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Kyndryl (KD) trades at $14.02, showing modest daily gains of 0.21%. The stock maintains a bullish technical signal with strong moving average support. Fundamentally, the company achieved profitability in 2025 with $252M net income after three years of losses, though revenue declined to $15.1B. Recent developments include the planned acquisition of Healthcare IT Leaders to boost AI capabilities and Q1 2027 results showing a $0.12 per share loss on $3.6B revenue.
While Kyndryl demonstrates improving profitability and strategic AI investments, investors face mixed signals with analyst consensus leaning hold (71%) and revenue declines. The stock trades near analyst targets with upside limited to technical momentum. Key risks include ongoing revenue pressure and the integration challenges of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
